Pozen, Inc. (POZN) – Bull of the Day
Source: http://www.zacks.com/commentary/12465/Pozen%2C+Inc.+%28POZN%29+-+Bull+of+the+DayPosted on Tuesday, October 20th, 2009 | In Investing Lessons, Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -
Pozen, Inc. (POZN) is one of our top-picks for small-cap biotech. We
see the fundamentals as strong and the valuation as low.
We are pleased to see the NDA for Vimovo (PN-400) filed and now accepted by the U.S. FDA. FDA acceptance earned Pozen a $10 million milestone from AstraZeneca in August. We expect sales of Treximet to ramp in the coming quarters now that the groundwork has been laid. And finally, phase III trials on the very exciting PA program should start in the fall.
The company is financially well positioned and fundamentally strong with respect to the pipeline. We recommend being buyers at this level.Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
Tags for this Post:
Astrazeneca, Fda, Investing Lessons, Stocks to Watch, USD, Zacks Market Commentaries
Astrazeneca, Fda, Investing Lessons, Stocks to Watch, USD, Zacks Market Commentaries
![]() About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |



